Literature DB >> 29338092

Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer.

Hui Li1, Ying-Qiang Zhang1, Chen Wang1, Xin Zhang1, Xin Li2, Yan-Song Lin1.   

Abstract

OBJECTIVE: Whether the initiating time of radioiodine (RAI) therapy will affect the clinical outcome in differentiated thyroid cancer (DTC) remains controversial. The objective of this study was to evaluate the impact of RAI therapy initiating time on response to initial therapy in low- to intermediate-risk DTC.
METHODS: A total of 235 consecutive patients with low- to intermediate-risk DTC were retrospectively reviewed. According to the time interval between thyroidectomy and RAI therapy, patients were divided into Group 1 (interval < 3 months, n = 187) and Group 2 (interval ≥ 3 months, n = 48). Response to RAI therapy was evaluated as excellent, indeterminate, biochemical incomplete or structural incomplete response (ER, IDR, BIR or SIR) with a median follow-up of 780 days. The univariate and multivariate analyses were further conducted to identify factors associated with incomplete response (IR, including BIR and SIR).
RESULTS: Response to initial therapy was significantly different between 2 groups (P < .05), after excluding the impact of other risk factors (age, gender, histological type, status of T and N, RAI dose, thyrotropin, stimulated thyroglobulin and follow-up time). A significantly higher IR rate (18.8% vs 4.3%, P = .001) and a lower ER proportion (62.5% vs 78.1%, P = .027) were observed in Group 2. By univariate analysis, both T status and N status, stimulated thyroglobulin and time interval were significant risk factors for IR (P < .05). Multivariate analysis demonstrated that the time interval was an independent risk factor for IR (P = .008).
CONCLUSIONS: Delayed initial RAI therapy (≥3 months after thyroidectomy) related to incomplete response in low- to intermediate-risk DTC.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  differentiated thyroid cancer; postoperative period; prognosis; radioiodine therapy; time factors; treatment outcome

Mesh:

Substances:

Year:  2018        PMID: 29338092     DOI: 10.1111/cen.13551

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy?

Authors:  Luca Giovanella; Anca M Avram; Jerome Clerc; Elif Hindié; David Taïeb; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-30       Impact factor: 9.236

2.  Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer.

Authors:  Feng Yu; Xue Li; Yanhui Ji; Jian Tan; Guizhi Zhang; Peng Wang; Yajing He; Renfei Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-09       Impact factor: 5.555

3.  Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta-analysis.

Authors:  Fang Cheng; Juan Xiao; Fengyan Huang; Chunchun Shao; Shouluan Ding; Canhua Yun; Hongying Jia
Journal:  Cancer Med       Date:  2022-02-18       Impact factor: 4.711

4.  Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After 131I Treatment.

Authors:  Jingjia Cao; Canhua Yun; Xiaolu Zhu; Xiao Li; Yaru Sun; Wei Zhang
Journal:  Cancer Manag Res       Date:  2021-06-14       Impact factor: 3.989

5.  Analysis of Curative Effect and Influencing Factors of N1 Stage Papillary Thyroid Micro-Carcinoma and Papillary Thyroid Non-Micro Carcinoma After Initial Radioactive Iodine Ablation Therapy.

Authors:  Canhua Yun; Meiling Wu; Juan Xiao; Yong Liu; Wei Zhang; Jingjia Cao
Journal:  Cancer Manag Res       Date:  2021-02-12       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.